2,6-ditert-butyl-4-[3-(3,5-ditert-butyl-4-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenol | 721446-17-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,6-ditert-butyl-4-[3-(3,5-ditert-butyl-4-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenol
• CAS: 721446-17-9
• 化学式: C₃₁H₄₆N₂O₂
• 分子量: 478.718
• InChiKey: GYTQBGJHUMYKDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.3
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  64.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,6-ditert-butyl-4-[3-(3,5-ditert-butyl-4-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenol 在 manganese(IV) oxide 作用下， 以 二氯甲烷 为溶剂， 以78%的产率得到3,5-bis(3,5-di-tert-butyl-4-hydroxyphenyl)pyrazole
  参考文献：
  名称：

  Novel 3,5-diaryl pyrazolines and pyrazole as low-density lipoprotein (LDL) oxidation inhibitor

  摘要：

  Compounds 4a-j and 5 were synthesized by cyclocondensation of 3a-j and hydrazine and showed significant LDL-antioxidant activities in the TBARS assay, the lag time of conjugated diene production, the relative electrophoretic mobility (REM) of ox-LDL, the apoB-100 fragmentation, and the macrophage-mediated LDL oxidation. Among compounds 4a-j and 5, 4a was found to be the most active compound as an inhibitor of LDL oxidation and 4a (IC50 = 0.1 muM) was 6-fold more potent than probucol (IC50 = 0.6 muM) in the TBARS assay. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.072
• 作为产物：
  描述：

  3,5-二叔丁基-4-羟基苯乙酮 在 硫酸 、 肼 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 2.0h， 生成 2,6-ditert-butyl-4-[3-(3,5-ditert-butyl-4-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenol
  参考文献：
  名称：

  新型3,5-二芳基吡唑啉类化合物作为人类酰基辅酶A：胆固醇酰基转移酶的抑制剂。

  摘要：

  制备了一系列吡唑啉衍生物以评估其酰基-CoA：胆固醇酰基转移酶活性。显示了3-（3，5-二叔丁基-4-羟基苯基）-5-（多取代的4-羟基苯基）-2-吡唑啉4a-i在体外对hACAT-1和-2的抑制活性。

  DOI：

  10.1016/j.bmcl.2004.03.079

文献信息

• Novel 3,5-diaryl pyrazolines as human acyl-CoA:cholesterol acyltransferase inhibitors
  作者：Tae-Sook Jeong、Kyung Soon Kim、So-Jin An、Kyung-Hyun Cho、Sangku Lee、Woo Song Lee

  DOI：10.1016/j.bmcl.2004.03.079

  日期：2004.6

  A series of pyrazoline derivatives were prepared for evaluating their acyl-CoA:cholesterol acyltransferase activities. 3-(3,5-Di-tert-butyl-4-hydroxyphenyl)-5-(multi-substituted 4-hydroxyphenyl)-2-pyrazolines 4a-i were shown in vitro inhibitory activity on hACAT-1 and -2.

  制备了一系列吡唑啉衍生物以评估其酰基-CoA：胆固醇酰基转移酶活性。显示了3-（3，5-二叔丁基-4-羟基苯基）-5-（多取代的4-羟基苯基）-2-吡唑啉4a-i在体外对hACAT-1和-2的抑制活性。
• Novel 3,5-diaryl pyrazolines and pyrazole as low-density lipoprotein (LDL) oxidation inhibitor
  作者：Tae-Sook Jeong、Kyung Soon Kim、Ju-Ryoung Kim、Kyung-Hyun Cho、Sangku Lee、Woo Song Lee

  DOI：10.1016/j.bmcl.2004.03.072

  日期：2004.6

  Compounds 4a-j and 5 were synthesized by cyclocondensation of 3a-j and hydrazine and showed significant LDL-antioxidant activities in the TBARS assay, the lag time of conjugated diene production, the relative electrophoretic mobility (REM) of ox-LDL, the apoB-100 fragmentation, and the macrophage-mediated LDL oxidation. Among compounds 4a-j and 5, 4a was found to be the most active compound as an inhibitor of LDL oxidation and 4a (IC50 = 0.1 muM) was 6-fold more potent than probucol (IC50 = 0.6 muM) in the TBARS assay. (C) 2004 Elsevier Ltd. All rights reserved.